Cash round sets up trial of InteRNA’s microRNA for cancer
pharmaphorum
FEBRUARY 9, 2021
million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.
58 
Let's personalize your content